Cadonilimab (AK104) is another anti-PD-1/anti-CTLA4 bispecific antibody being investigated in addition to chemotherapy (NCT05901584) or in addition to chiauranib (mTKI, anti-VERGFR 1-2-3, PDGFRα, and c-KIT) (NCT05505825) in pretreated SCLC; these trials are recruiting in China and Australia. Here, KIT is linked to small cell lung carcinoma.